26 August 2011

Cancer Comments

 (S)-2-Amino-3-(3-phenacetylimidazol-4-yl) propanoic acid

This new compound has reproducibly been independently confirmed as effective against all neoplasms tested :

ATCC U-87 ( Human Astrocytoma, Glioblastoma Multiforme )
ATCC HEP G2 ( Hepatocellular Carcinoma )
ATCC A-375 (Human Malignant Melanoma)

The Science... in detail (link)

This compound does not exhibit inhibition of normal 'healthy' B cells (D8 LCL B cells) - at concentrations used for inhibition of cancer.

This compound kills cancer cells.

Mechanism is consistent with induction of apoptosis - in neoplastic cells.

A novel small molecule, alpha amino acid, antineoplastic - no demonstrated toxicity to 'healthy tissue'.
No anticipated 'side-effects' (e.g. 'chemo-brain', hair-loss, hypernatremia, gastro-intestinal upset, nausea, somnolence).
Wide therapeutic margin.
Possible primary therapy, adjuvant therapy,  'compassionate use' therapy, possible prophylactic/maintenance therapy.
Excellent likelihood for good stability (and thus long shelf life).
Ease of use and administration - with oral dosing possible.
Low cost of goods.
Antibiotic properties.
New 'reagent' - opens possibilities for all science.
Possible nutritional supplement usage.
  • Rapid inhibition of difficult to treat cancer cell lines.
  • Reproducible cell viability/dose response curves.
  • Mechanism consistent with activation of apoptotic pathway.
  • Physico-chemical properties consistent with high oral absorption and BBB (Blood-brain barrier) permeability.
  • Pharmacokinetics, ADME (Absorption, Distribution, Metabolism, Excretion), likely simple and efficient.
  • Metabolism most probably through decarboxylation.

Finances are needed to finish the 'approval process' for this antineoplastic NCE:
CRO toxicology confirmation, IND/NDA filing with FDA, human clinical trials.
This is (and has been) ready! 


Dennis Wright